Redburn raises Charles River Labs to buy, cuts price target to $182

Redburn-Atlantic upgraded Charles River Laboratories (CRL) to Buy with a price target of $182, citing improving demand in its Discovery and Safety Assessment businesses and a strategic review influenced by Elliott Management. The upgrade follows a strong Q1 2025 earnings report with EPS of $2.34 on revenues of $984.2 million, exceeding expectations, and leading to raised full-year guidance; multiple analysts have also increased their price targets, with Deutsche Bank setting a $180 target and Evercore ISI setting a $170 target, reflecting confidence in the company's growth potential.

Analysis

Charles River Laboratories (CRL) has received a significant vote of confidence with Redburn-Atlantic's upgrade to Buy from Neutral, primarily driven by early indications of improving demand in its Discovery and Safety Assessment (DSA) business. This segment, which had seen year-over-year declines since the fourth quarter of 2023, showed initial signs of reversal in the first quarter of 2025. This positive momentum is strongly supported by CRL's first-quarter 2025 financial results, where earnings per share reached $2.34, surpassing the $2.09 forecast, and revenue of $984.2 million exceeded the anticipated $941.47 million. Consequently, Charles River Laboratories raised its full-year EPS guidance to a range of $9.30 to $9.80. Further reinforcing the bullish outlook are upward earnings estimate revisions from twelve analysts and the influence of Elliott Management, CRL's largest investor, which has initiated a comprehensive strategic review viewed as a potential performance catalyst. Redburn-Atlantic has increased its forecasts by approximately 7%, placing them 5-6% above consensus estimates. Although their price target was slightly adjusted to $182 from $188, this new target is based on an 18 times multiple of the company’s non-GAAP 2025 estimated EPS, aiming to reduce the current valuation discount; CRL currently trades at 14 times its 2025 earnings, a 36% discount to its ten-year average historical forward multiple of 22 times and a similar discount to the S&P 500 index. The company's financial stability is underscored by a "GOOD" Financial Health Score from InvestingPro and a robust free cash flow yield of 8%, well above its historical average of 4.5%, with $563 million in levered free cash flow generated over the last twelve months. This sentiment is corroborated by other financial institutions, including Deutsche Bank, which raised its price target to $180, and Evercore ISI, which upgraded the stock to Outperform with a $170 target, both citing strategic realignments and improved bookings.

Key Decisions for Investors

• Given the improving operational trends, activist investor involvement prompting a strategic review, and a valuation at a significant discount to historical multiples, Charles River Laboratories presents a potentially attractive entry point.
• Investors could view the stock favorably, supported by the strong Q1 2025 earnings beat, raised full-year guidance, and multiple analyst upgrades which signal growing confidence in the company's recovery and growth trajectory.
• Continued monitoring of the strategic review's execution and sustained evidence of demand normalization in the Discovery and Safety Assessment business is crucial to validate the ongoing recovery thesis.